Thanks for emailing that article!
San Francisco — Catalyst For a Cure (CFC) was launched a decade ago as a novel initiative to advance basic science research on the pathophysiology of glaucoma, ultimately to lead to a cure.
At Catalyst for a Cure: The Annual Benefit on Thursday evening, the four principal investigators provided an update on their progress in elucidating the molecular mechanisms of neurodegeneration in glaucoma and identifying promising targets for therapeutic interventions that can delay or prevent retinal ganglion cell loss.
The Catalyst For a Cure scientists are very excited about the potential for future breakthroughs, noting that their collaboration has reached a critical stage in which the individual groups have begun to bring together their findings and ideas in order to develop a unifying theory on disease mechanisms.
Last reviewed on February 03, 2012